

IN THE CLAIMS:

Please amend the claims to read as follows:

1.-82. (Cancelled)

83. (Currently Amended) A method of assessing the effectiveness of a non-nucleoside reverse transcriptase inhibitor (NNRTI) on a human immunodeficiency virus type 1 (HIV-1)-infected patient, comprising ~~evaluating whether detecting in a plasma sample collected from the HIV-1-infected patient comprises encoding a~~ the presence of an HIV-1 reverse transcriptase (RT) nucleic acid that has encodes one of the following combination of mutations: G190A/S and K101E, or G190A/S and A98G, wherein said mutation combination of mutations is associated with increased susceptibility to delavirdine and decreased susceptibility to nevirapine and efavirenz.

84. (Previously Presented) The method of claim 83, wherein the mutation at codon 190 encodes alanine (A).

85. (Previously Presented) The method of claim 83, further comprising evaluating whether the nucleic acid encoding reverse transcriptase has an additional mutation K103N, wherein the presence of the additional mutation in combination with the mutations G190A/S and K101E, or G190A/S and A98G, is correlated with decreased susceptibility to delavirdine, nevirapine, and efavirenz.

86. (Currently Amended) The method of claim 83, wherein the mutation at codon 190 encodes serine (S).

87.-105. (Cancelled)